Castleark Management LLC raised its holdings in Horizon Therapeutics PLC (NASDAQ:HZNP) by 2.1% in the 2nd quarter, HoldingsChannel reports. The firm owned 362,980 shares of the biopharmaceutical company’s stock after purchasing an additional 7,442 shares during the quarter. Castleark Management LLC’s holdings in Horizon Therapeutics were worth $8,733,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also modified their holdings of HZNP. Geode Capital Management LLC raised its position in Horizon Therapeutics by 8.9% in the 4th quarter. Geode Capital Management LLC now owns 1,935,457 shares of the biopharmaceutical company’s stock valued at $37,818,000 after purchasing an additional 158,342 shares during the last quarter. SG Americas Securities LLC raised its position in shares of Horizon Therapeutics by 107.7% during the first quarter. SG Americas Securities LLC now owns 19,606 shares of the biopharmaceutical company’s stock worth $518,000 after acquiring an additional 10,168 shares during the last quarter. Rhumbline Advisers raised its position in shares of Horizon Therapeutics by 6.4% during the first quarter. Rhumbline Advisers now owns 253,949 shares of the biopharmaceutical company’s stock worth $6,712,000 after acquiring an additional 15,164 shares during the last quarter. Victory Capital Management Inc. bought a new stake in shares of Horizon Therapeutics during the first quarter worth $27,663,000. Finally, First Mercantile Trust Co. bought a new stake in shares of Horizon Therapeutics during the first quarter worth $217,000. Hedge funds and other institutional investors own 86.29% of the company’s stock.
In other Horizon Therapeutics news, CFO Paul W. Hoelscher sold 1,359 shares of the business’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $28.00, for a total value of $38,052.00. Following the completion of the transaction, the chief financial officer now directly owns 159,310 shares of the company’s stock, valued at $4,460,680. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Timothy P. Walbert sold 2,500 shares of the business’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $28.00, for a total value of $70,000.00. Following the completion of the transaction, the chief executive officer now directly owns 785,296 shares of the company’s stock, valued at $21,988,288. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 235,278 shares of company stock valued at $6,473,106. 4.10% of the stock is owned by insiders.
Horizon Therapeutics (NASDAQ:HZNP) last announced its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.14. Horizon Therapeutics had a return on equity of 30.33% and a net margin of 5.90%. The business had revenue of $320.60 million during the quarter, compared to analysts’ expectations of $296.27 million. During the same period in the previous year, the firm earned $0.48 earnings per share. The firm’s quarterly revenue was up 5.9% compared to the same quarter last year. On average, equities research analysts forecast that Horizon Therapeutics PLC will post 1.6 EPS for the current fiscal year.
A number of equities research analysts have recently weighed in on HZNP shares. Guggenheim started coverage on Horizon Therapeutics in a research report on Thursday. They set a “buy” rating and a $36.00 target price for the company. Cowen set a $35.00 target price on Horizon Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Piper Jaffray Companies set a $33.00 target price on Horizon Therapeutics and gave the stock a “buy” rating in a research report on Monday, August 26th. TheStreet cut Horizon Therapeutics from a “b-” rating to a “c+” rating in a research note on Monday, June 10th. Finally, BMO Capital Markets raised Horizon Therapeutics from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $29.00 to $36.00 in a research note on Wednesday, August 14th. Four equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Horizon Therapeutics has an average rating of “Buy” and an average price target of $33.00.
Horizon Therapeutics Company Profile
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Read More: How to trade the most active stocks
Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Therapeutics PLC (NASDAQ:HZNP).
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.